// App-Quantinova.ai

: WINDOW OF OPPORTUNITY STUDY EVALUATING THE ANTIPROLIFERATIVE EFFECTS OF NEOADJUVANT METFORMIN PLUS SIMVASTATIN PRIOR TO RADICAL CYSTECTOMY FOR BLADDER CANCER: INTERIM ANALYSIS SHOWS REDUCTION IN PI3K/AKT/MTOR SIGNALING PATHWAY

Researchers

Presenter

  • Victor McPherson

Principal Investigators

  • Khalil Hetou

  • Shiva Nair

  • Christopher Howlett

  • Joseph Chin

  • Nicholas Power

  • Eric Winquist

  • Scott Ernst

  • Kylea Potvin

  • Bret Wehrli

  • Jonathan Izawa

Medical Centers

  • N/A

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Bladder Cancer

  • Solid malignancies

Biomarkers

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

  • Proliferation marker protein Ki-67

  • PI3K/AKT

Drug/Treatment

  • Simvastatin

  • Metformin Hydrochloride

Outcome

  • N/A

Study Design

  • Single Arm

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved